| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11030723 | International Journal of Surgery Open | 2018 | 8 Pages |
Abstract
Although our study was not randomized we were able to show a highly statistically significant survival advantage of incomplete adjuvant chemotherapy in patients with UICC stage III colon cancer. If side effects of chemotherapy are tolerable for the patient, temporary limitations of the individual quality of life are outweighed by the survival advantage even if therapy is not completed.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Martin Hoffmann, Lucky Ogbonnaya, Claudia Benecke, Ruediger Braun, Markus Zimmermann, Erik Schloericke, Tobias Keck,